Literature DB >> 19791750

Reductive activation of mitomycin C by thiols: kinetics, mechanism, and biological implications.

Manuel M Paz1.   

Abstract

The clinically used antitumor antibiotic mitomycin C requires a reductive activation to be converted to a bis-electrophile that forms several covalent adducts with DNA, including an interstrand cross-link which is considered to be the lesion responsible for the cytotoxic effects of the drug. Enzymes such as cytochrome P450 reductase and DT-diaphorase have traditionally been implicated in the bioreduction of mitomycin C, but recent reports indicate that enzymes containing a dithiol active site are also involved in the metabolism of mitomycin C. The reductive activation can also be effected in vitro with chemical reductants, but until now, mitomycin C was considered to be inert to thiols. We report here that mitomycin C can, in fact, be reductively activated by thiols. We show that the reaction is autocatalytic and that the end product is a relatively stable aziridinomitosene that can be trapped by adding several nucleophiles after the activation reaction. Kinetic studies show that the reaction is highly sensitive to pH and does not proceed or proceeds very slowly at neutral pH, an observation that explains the unsuccessful results on previous attempts to activate mitomycin C with thiols. The optimum pH for the reactions is around the pK(a) values of the thiols used in the activation. A mechanism for the reaction is hypothesized, involving the initial formation of a thiolate-mitomycin adduct, that then evolves to give the hydroquinone of mitomycin C and disulfide. The results presented here provide a chemical mechanism to explain how some biological dithiols containing an unusually acidic thiol group (deprotonated at physiological pH) participate in the modulation of mitomycin C cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19791750     DOI: 10.1021/tx9002758

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

Review 1.  Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

Authors:  Phillip D Bass; Daniel A Gubler; Ted C Judd; Robert M Williams
Journal:  Chem Rev       Date:  2013-05-08       Impact factor: 60.622

2.  Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.

Authors:  Shira Dorot; James Tankel; Victoria Doviner; Hilary Shmeeda; Yasmine Amitay; Patricia Ohana; Amir Dagan; Menachem Ben-Haim; Petachia Reissman; Alberto Gabizon
Journal:  Cancer Chemother Pharmacol       Date:  2022-07-08       Impact factor: 3.288

3.  Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.

Authors:  Yasmine Amitay; Hilary Shmeeda; Yogita Patil; Jenny Gorin; Dina Tzemach; Lidia Mak; Patricia Ohana; Alberto Gabizon
Journal:  Pharm Res       Date:  2015-11-16       Impact factor: 4.200

4.  A Silent Operon of Photorhabdus luminescens Encodes a Prodrug Mimic of GTP.

Authors:  Negar Shahsavari; Boyuan Wang; Yu Imai; Miho Mori; Sangkeun Son; Libang Liang; Nils Böhringer; Sylvie Manuse; Michael F Gates; Madeleine Morrissette; Rachel Corsetti; Josh L Espinoza; Chris L Dupont; Michael T Laub; Kim Lewis
Journal:  mBio       Date:  2022-05-16       Impact factor: 7.786

5.  Metformin alters therapeutic effects in the BALB/c tumor therapy model.

Authors:  Felix B Meyer; Sophie Goebel; Sonja B Spangel; Christiane Leovsky; Doerte Hoelzer; René Thierbach
Journal:  BMC Cancer       Date:  2021-05-28       Impact factor: 4.430

6.  Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones).

Authors:  Leonard Howard Damelin; Rupal Jivan; Robin Bruce Veale; Amanda Louise Rousseau; Demetra Mavri-Damelin
Journal:  BMC Cancer       Date:  2014-05-05       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.